Drug intelligence / Profile preview

verteporfin + ranibizumab

Development stage: Unknown
Lead developer: Novartis
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravitreal, Intravenous

Overview

This combination therapy involves **verteporfin**, a photosensitizer used in photodynamic therapy (PDT), and **ranibizumab**, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment. Verteporfin is activated by light to cause local damage to neovascular endothelium, while ranibizumab inhibits VEGF to prevent new vessel formation. The combination is used to treat neovascular age-related macular degeneration (AMD), aiming to improve visual outcomes and reduce treatment frequency.

Brand names: LucentisVisudyne
Other names: Combination therapy using verteporfin and ranibizumab

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on verteporfin + ranibizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on verteporfin + ranibizumab.

Explore the full profile